Background: On April 24, 2012, Michael Roosevelt of FDA sent a warning letter to 10 companies regarding the dietary ingredient 1,3 DMAA.

You can view that letter by clicking here

USPlabs has invested heavily in clinical and analytical research on 1,3 DMAA. We made four submissions to FDA providing the most up to date information regarding the safety and legality of the ingredient. This included 11 peer-reviewed, published clinical and analytical studies.

Those submissions, including all appendices, can be viewed by clicking on the dates below:

On April 18, 2013 Jennifer Thomas of FDA responded to the four USPlabs submissions with this letter: Click here.

On May 9, 2013 USPlabs responded with this submission: Click here.

On April 16, 2013 USPlabs announced publically that for business reasons it was stopping new manufacture of 1,3 DMAA products and was phasing out 1,3 DMAA: Click here.

The company stands by the safety and legality of 1,3 DMAA when used as directed and points to the substantial scientific, medical, and analytical support that appears on this website.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Individual results may vary.
Copyright 2013, USPlabs, LLC. All Rights Reserved.